Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells

August 10, 2020

PHILADELPHIA -- (Aug. 10, 2020) -- According to a study by The Wistar Institute, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells. These messages are packaged into particles called extracellular vesicles (EVs) and reprogram mitochondrial shape and position within the recipient normal cells to ultimately promote deregulated tissue morphogenesis. These findings were published today in Developmental Cell.

"It is well known that cancer cells 'talk' to their neighboring normal cells all the time and this is important to promote cancer progression," said study lead author Dario C. Altieri, M.D., Wistar president and CEO, director of the Institute's Cancer Center and the Robert & Penny Fox Distinguished Professor. "How that happens and what signals are being transferred from one cell to another are still very much open questions. A better understanding of this process may give us important clues about how tumors hijack nearby normal cells to promote disease recurrence."

For their studies, Altieri's team cultured breast cancer cells in a low-oxygen setting to mimic a condition known as hypoxia, which is a hallmark of the microenvironment surrounding most solid tumors, and studied the EVs released by these cells.

EVs are tiny structures enclosed in a double membrane layer and released by most cells to transfer different molecules and information to other cells. As such, vesicles are an important means of intercellular communication. In this study, researchers focused on small EVs (sEV) that are between 30 and 150?nm in size.

To dissect the effects of sEVs produced by cancer cells on normal neighboring cells, researchers incubated normal breast epithelial cells with sEVs released by cells maintained in hypoxia. They observed an increase in the ability of normal recipient cells to migrate in culture, which in turn correlated with a redistribution of their mitochondria to the cell periphery. This is consistent with the role played by mitochondria in supporting cell motility, previously described by the Altieri lab.

In addition to modulation of mitochondrial behavior, the research team discovered that sEV released by hypoxic breast cancer cells induced major changes in gene expression in the normal recipient cells, with activation of multiple pathways of cell motility, cytoskeletal organization and cell-to-cell contact. Additionally, sEV-treated cells exhibited reduced cell death and increased pro-inflammatory responses.

Altieri and colleagues went on to identify Integrin-Linked Kinase (ILK) as the main signaling component packaged in sEVs, responsible for both mitochondrial changes and increased migration of recipient cells.

In turn, activation of ILK signaling profoundly affected normal tissue morphogenesis. Using 3-D cell models of normal mammary gland development, the team observed that exposure to sEVs from hypoxic cancer cells caused a general disruption of the normal mammary gland architecture and induced multiple traits of oncogenic transformation, including morphological changes, deregulated cell proliferation, reduced cell death, and appearance of markers of epithelial-mesenchymal transition (EMT), a process that confers mobility to cancer cells and the capacity to migrate from the primary site.

"Our findings indicate that breast cancer cells may use sEVs to enable both local and distant disease progression," said Irene Bertolini, Ph.D., first author of the study and a postdoctoral fellow in the Altieri lab. "Based on these observations, we suggest that therapeutic targeting of ILK or mitochondrial reprogramming may provide novel strategies to disrupt these pro-tumorigenic changes in the microenvironment."
Co-authors: Jagadish C. Ghosh and Andrew V. Kossenkov from Wistar; Sudheer Mulugu from Perelman School of Medicine, University of Pennsylvania; Shiv Ram Krishn and Lucia R. Languino from Sidney Kimmel Cancer Center, Thomas Jefferson University; Valentina Vaira from Fondazione IRCCS Ca? Granda Ospedale Maggiore Policlinico, Milan, Italy and University of Milan, Italy; and Jun Qin and Edward F. Plow from Lerner Research Institute, Cleveland Clinic.

Work supported by: National Institutes of Health (NIH) grants P01 CA140043, R35 CA220446, R01 HL58758, and R50 CA211199; Additional support was provided by the Italian Minister of Health. Core support for The Wistar Institute was provided by the Cancer Center Support Grant P30CA010815.

Publication information: Small Extracellular Vesicle Regulation of Mitochondrial Dynamics Reprograms a Hypoxic Tumor Microenvironment, Developmental Cell (2020). Online publication.

The Wistar Institute is an international leader in biomedical research with special expertise in cancer, immunology, infectious disease research, and vaccine development. Founded in 1892 as the first independent nonprofit biomedical research institute in the United States, Wistar has held the prestigious Cancer Center designation from the National Cancer Institute since 1972. The Institute works actively to ensure that research advances move from the laboratory to the clinic as quickly as possible. Wistar's Business Development team is dedicated to accelerating the translation of Wistar discoveries into innovative medicines and healthcare solutions through licensing, start-ups and creative collaborations.

The Wistar Institute

Related Cancer Cells Articles from Brightsurf:

Cancer researchers train white blood cells to attacks tumor cells
Scientists at the National Center for Tumor Diseases Dresden (NCT/UCC) and Dresden University Medicine, together with an international team of researchers, were able to demonstrate that certain white blood cells, so-called neutrophil granulocytes, can potentially - after completing a special training program -- be utilized for the treatment of tumors.

New way to target some rapidly dividing cancer cells, leaving healthy cells unharmed
Scientists at Johns Hopkins Medicine and the University of Oxford say they have found a new way to kill some multiplying human breast cancer cells by selectively attacking the core of their cell division machinery.

Breast cancer cells use message-carrying vesicles to send oncogenic stimuli to normal cells
According to a Wistar study, breast cancer cells starved for oxygen send out messages that induce oncogenic changes in surrounding normal epithelial cells.

Breast cancer cells turn killer immune cells into allies
Researchers at Johns Hopkins University School of Medicine have discovered that breast cancer cells can alter the function of immune cells known as Natural killer (NK) cells so that instead of killing the cancer cells, they facilitate their spread to other parts of the body.

Breast cancer cells can reprogram immune cells to assist in metastasis
Johns Hopkins Kimmel Cancer Center investigators report they have uncovered a new mechanism by which invasive breast cancer cells evade the immune system to metastasize, or spread, to other areas of the body.

Engineered immune cells recognize, attack human and mouse solid-tumor cancer cells
CAR-T therapy has been used successfully in patients with blood cancers such as lymphoma and leukemia.

Drug that keeps surface receptors on cancer cells makes them more visible to immune cells
A drug that is already clinically available for the treatment of nausea and psychosis, called prochlorperazine (PCZ), inhibits the internalization of receptors on the surface of tumor cells, thereby increasing the ability of anticancer antibodies to bind to the receptors and mount more effective immune responses.

Engineered bone marrow cells slow growth of prostate and pancreatic cancer cells
In experiments with mice, researchers at the Johns Hopkins Kimmel Cancer Center say they have slowed the growth of transplanted human prostate and pancreatic cancer cells by introducing bone marrow cells with a specific gene deletion to induce a novel immune response.

First phase i clinical trial of CRISPR-edited cells for cancer shows cells safe and durable
Following the first US test of CRISPR gene editing in patients with advanced cancer, researchers report these patients experienced no negative side effects and that the engineered T cells persisted in their bodies -- for months.

Zika virus' key into brain cells ID'd, leveraged to block infection and kill cancer cells
Two different UC San Diego research teams identified the same molecule -- αvβ5 integrin -- as Zika virus' key to brain cell entry.

Read More: Cancer Cells News and Cancer Cells Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to